The molecular epidemiology of multiple zoonotic origins of SARS-CoV-2
As 2019 turned into 2020, a coronavirus spilled over from wild animals into people, sparking what has become one of the best documented pandemics to afflict humans.
Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models
The COVID-19 pandemic has been ongoing for more than 2 years now, and new variants such as Omicron are less susceptible to the vaccines developed against earlier lineages of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Orally efficacious lead of the AVG inhibitor series targeting a dynamic interface in the respiratory syncytial virus polymerase
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory infections in infants and the immunocompromised, yet no efficient therapeutic exists. We have identified the AVG class of allosteric inhibitors of RSV RNA synthesis.
Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study
Although human respiratory syncytial virus (RSV) is an important cause of illness and death in older adults, no RSV vaccine has been licensed.
Duration of immune protection of SARS-CoV-2 natural infection against reinfection in Qatar
We investigated duration of protection afforded by natural infection, the effect of viral immune evasion on duration of protection, and protection against severe reinfection, in Qatar, between February 28, 2020 and June 5, 2022.
RSV and the burden of disease in older adults
Who is at an increased risk of adverse effects from an RSV infection? What is the burden of disease and what should be done to alleviate the risk and increase awareness?
Research explores possible link between type 1 diabetes and COVID-19
A trio of new studies from the United States and Europe explore a possible link between COVID-19 and new-onset type 1 diabetes (T1D) in children.
Human seasonal influenza under COVID-19 and the potential consequences of influenza lineage elimination
Global influenza circulation has been heavily suppressed by public health measures and travel restrictions since the onset of the COVID-19 pandemic.
Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
These new subvariants carrying further mutations in their spike proteins raise concerns that they may further evade neutralizing antibodies.
Spotlight on the burden of flu for people living with diabetes
Why are people with diabetes more at risk from flu? What are the options for reducing the risk? What are the challenges and solutions to increase awareness across health care professionals, researchers and patients themselves?
Project FluCov: understanding and communicating the impact of COVID-19 on influenza activity
Nivel is researching the impact of COVID-19 on Influenza activity combining data from around the world.
Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study